Navigation Links
Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
Date:9/12/2007

- (381,062)

Purchase of capital assets (49,526) (234,919)

Purchase of intangible assets (345,425)

Proceeds on disposal of capital assets 60,754 3,573

Net cash received under contractual arrangement 400,000 475,000

Cash received on acquisition of ENI - 1,040,471

ENI acquisition costs - (253,296)

Cash received on acquisition of NMX 109,730 -

NMX acquisition costs (322,842) -

-------------------------------------------------------------------------

Cash provided by (used in) investing

activities (21,941,808) 2,911,124

-------------------------------------------------------------------------

FINANCING ACTIVITIES

Proceeds from bought deal financing, net - 9,648,600

Repayment of long term debt (300,707) (2,740,795)

Repayment of obligation under capital leases - (17,019)

Proceeds from issuance of common shares, net 24,345,142 8,016

-------------------------------------------------------------------------

Cash provided by (used in) financing

activities 24,044,435 6,898,802

-------------------------------------------------------------------------

Net increase (decrease) in cash and cash

equivalents during the period (2,697,195) (2,523,639)

Cash and cash equivalents, beginning of

period 4,074,582 6,598,221

-------------------------------------------------------------------------

Cash and cash equivalents, end of period 1,377,387 4,074,582

-----------------------------------
'/>"/>

SOURCE Transition Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine news :

1. Mans Transition from Foragers to Agriculturalist Led to Increase in Birth Rates
2. Rocky Transition to the Medicare Drug Program
3. Customized Post Operation Care Offers Patients a Smooth Transition to Patients into the Community
4. Mental Health - NHS Trust Commences Specialist Transition Service
5. Permanent Weight Loss Requires Transition to Healthy Eating
6. VBI Provides Potential Targets to Diabetes Therapeutics
7. CELL THERAPEUTICS PAYS Heavily to Resolve Dispute FOR ALLEGED ILLEGAL MARKETING OF CANCER DRUG
8. PM announces a new health care order for India
9. Ramdoss Announces Introduction of RCH-II
10. Britain Announces Third Transfusion Related Mad Cow Case
11. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...ec. 4 Care Investment T...) today announced that its Board of Directors has ...tock. The dividend is payable on December 22, 200... 2009. ,, About Care Investment Trust ,...stment and finance company investing in healthcare...
(Date:12/4/2009)...ISCO, Dec. 4 Medithrive, Inc. has ...pensary in the SF Bay Area by popular vote conduct...ite only three months in operation, the SF Bay com...ocation for accessing medicinal marijuana. ,,...rms the obvious: a dispensary which caters to the ...
(Date:12/4/2009)... Dec. 4 The American As...SA) applauds the Senate for ensuring that the Com...isions remain in the final health reform legislati...ing support to elders, people with disabilities an...ass a health care reform bill that will make it af...
(Date:12/4/2009)...TY, Mo., Dec. 4 The large, two-day...ciation of Free Clinics (NAFC) in Kansas City on W... also for anyone who is uninsured and has not seen... clinic will receive preventive primary care. ,...rge free clinic events this fall in Houston, New O...
(Date:12/4/2009)... Calif., Dec. 4 Pamela Bowen, Chie...selected as a finalist for the "Chief Innovation O...iness with the power of cloud computing. Appy Awar...ve usage of Salesforce CRM or the Force.com platfo...heir sales, marketing, partner, service, support o...
Breaking Medicine News(10 mins):Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Free Health Clinic Event Is Not Just for the Sick 2Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2
...oung people appear to be developing the most commo...a dramatic increase in the cost and suffering //ca... overexposure to ultraviolet light from the sun, u...almost always curable and that together afflict 1 ...
... years since the Transplantation of Human Organ Ac...ay with the programme. This has been due to variou...irection and the will to seriously consider this a...idney scandal there is a knee jerk reaction from v...
...ug Digoxin or Digitalis, which comes from the foxg...t efficiently by maintaining the rhythm of the hea...f the drug is changed by the team of researchers f... which works by changing the sugars attached to th...
...s have shown that the efficacy of low-carb diets c... researchers question whether raising protein inta...cent study researchers set out to test the hypothe...ight loss. However some are of the opinion that pr...
...se are crucial factors. But according to the resea...reventive Medicine, // it has been found that calo...ath by heart disease. The finding was based on... done from 1971 to 1975. The participants were gro...
...ould not be a factor in determining transplant el...hown that older heart transplant patients do just ...archers evaluated all 275 adult patients who recei...o 11 years following surgery. Results showed no st...
Other Medicine News:Health News:The Potential Of Cadaver Transplantation Programme In India 2Health News:The Potential Of Cadaver Transplantation Programme In India 3Health News:Finding The Key To Weight Loss! 2
(Date:12/4/2009)... , MORRISTOWN, N.J., Dec. 4 /PRNewswire-Fir...PI ), a leading global specialty pharmaceutical co... Laboratories, Inc.-Florida, filed an Abbreviated ... Drug Administration seeking approval to market it... a patent owned by Takeda Pharmaceutical Company L...
(Date:12/4/2009)... , BETHESDA, Md., Dec. 4 Drs....s for prostate-specific antigen (PSA) recurrence f...s of biochemical recurrence rate in a Phase III pi...or injection) or monthly leuprolide in prostate ca... Prostate cancer patients who received FIRMAGON 24...
(Date:12/4/2009)... , WILMINGTON, Del., Dec. 4 /PRNewswire-Firs...ed that the US Food and Drug Administration (FDA) ...ine fumarate) Extended Release Tablets as adjuncti... with Major Depressive Disorder (MDD). SEROQUEL XR...he FDA to treat both major depressive disorder as ...
Breaking Medicine Technology:Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Novel K anonymity algorithm safeguards access to data 61811 1Flax and yellow flowers can produce bioethanol 10835 1Flax and yellow flowers can produce bioethanol 10835 2Parents 3A Holiday Safety Tips from Massachusetts Child Injury Lawyer Thomas M Kiley 61808 1Parents 3A Holiday Safety Tips from Massachusetts Child Injury Lawyer Thomas M Kiley 61808 2Parents 3A Holiday Safety Tips from Massachusetts Child Injury Lawyer Thomas M Kiley 61808 3
...06, Demonstrated No Reproductive Toxicity in ... Selected as Clinical Candidate, Demonstrated a 40...ce Daily Oral Dosing -, SAN DIEGO, May 22 Ardea ... preclinical data on its lead non-nucleoside,rever...806, demonstrating,no reproductive toxicity. In ad...
...ull Data Set from the TRIUMPH-1 Trial of Inhaled ...SPRING, Md., May 21 United,Therapeutics Corporati...y,Lung Rx, Inc. today announced that data from sev...nary arterial hypertension (PAH) with treprostinil...TS) meeting in Toronto,Ontario. The ATS presentati...
Other Medicine Technology:Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program 2Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program 3Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program 4Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 2Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 3Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 4Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 5Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration 6
Plasmacup SC
Trabecular Metal Modular Acetabular System
BiHAPro Acetabular Cup
Gap II Revision Cup
Medicine Products: